Volume 19, Number 3—March 2013
Research
Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection
Table 6
Time from start of treatment, mo | No. cultures converted /total (%) | No. cultures converted/ total converted (%) | Sensitivity, % | Specificity, % | Positive predictive value, % | Negative predictive value, % |
---|---|---|---|---|---|---|
1 | 4/114 (4) | 4/42 (10) | 12 | 99 | 75 | 79 |
2 | 18/114 (16) | 18/42 (43) | 42 | 92 | 61 | 84 |
3 | 29/114 (25) | 29/42 (69) | 65 | 86 | 59 | 89 |
4 | 33/114 (29) | 33/42 (79) | 77 | 85 | 61 | 93 |
6 | 39/114 (34) | 39/42 (93) | 92 | 83 | 62 | 97 |
24 | 42/114 (37) | NA | NA | NA | NA | NA |
*XDR TB, extensively drug-resistant tuberculosis; NA, not applicable.
Page created: March 21, 2013
Page updated: March 21, 2013
Page reviewed: March 21, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.